Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Non-Current Deferred Tax Liability (2023 - 2025)

Perspective Therapeutics' Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at $2.5 million for Q3 2025.

  • For Q3 2025, Non-Current Deferred Tax Liability fell 45.67% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $2.5 million, down 45.67%, while the annual FY2024 figure was $2.5 million, 45.67% down from the prior year.
  • Non-Current Deferred Tax Liability for Q3 2025 was $2.5 million at Perspective Therapeutics, roughly flat from $2.5 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $4.6 million in Q4 2023 and bottomed at $2.5 million in Q4 2024.
  • The 3-year median for Non-Current Deferred Tax Liability is $3.5 million (2023), against an average of $3.5 million.
  • The largest YoY upside for Non-Current Deferred Tax Liability was 45.67% in 2024 against a maximum downside of 45.67% in 2024.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $4.6 million in 2023, then crashed by 45.67% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Non-Current Deferred Tax Liability are $2.5 million (Q3 2025), $2.5 million (Q2 2025), and $2.5 million (Q1 2025).